



## Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENO Study

This is the peer reviewed version of the following article:

*Original:*

Paciaroni, M., Agnelli, G., Caso, V., Silvestrelli, G., Seiffge, D.J., Engelter, S., et al. (2019). Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENO Study. STROKE, 50(8), 2168-2174 [10.1161/STROKEAHA.119.025350].

*Availability:*

This version is available <http://hdl.handle.net/11365/1131363.6> since 2021-03-03T12:13:54Z

*Published:*

DOI:10.1161/STROKEAHA.119.025350

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

**Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with  
Non-vitamin K antagonist (NOACs) for stroke prevention: The ReNo Study**

Maurizio Paciaroni<sup>1</sup>MD, Giancarlo Agnelli<sup>1</sup> MD, Valeria Caso<sup>1</sup>PhD, Giorgio Silvestrelli<sup>2</sup> PhD, David Julian Seiffge<sup>3</sup> MD, Stefan Engelter<sup>3</sup> MD, Gian Marco De Marchis<sup>3</sup> MD, MSc, Alexandros Polymeris<sup>3</sup> MD, Maria Luisa Zedde<sup>4</sup> MD, Shadi Yaghi<sup>5</sup> MD, Patrik Michel<sup>6</sup> MD, Ashraf Eskandari<sup>6</sup> MD, Kateryna Antonenko<sup>7</sup> MD, Sung-Il Sohn<sup>8</sup> MD, Manuel Cappellari<sup>9</sup> MD, Tiziana Tassinari<sup>10</sup> MD, Rossana Tassi<sup>11</sup> MD, Luca Masotti<sup>12</sup> MD, Aristeidis H. Katsanos<sup>13</sup> MD, Sotirios Giannopoulos<sup>13</sup> MD, Monica Acciarresi<sup>1</sup> MD, Andrea Alberti<sup>1</sup> MD, Michele Venti<sup>1</sup> PhD, Maria Giulia Mosconi<sup>1</sup> MD, Maria Cristina Vedovati<sup>1</sup> MD, Patrizia Pierini<sup>1</sup> MD, Michela Giustozzi<sup>1</sup> MD, Enrico Maria Lotti<sup>14</sup> MD, George Ntaios<sup>15</sup> MD, Odysseas Kargiotis<sup>16</sup> MD, Serena Monaco<sup>17</sup> MD, Piergiorgio Lochner<sup>18</sup> MD, Fabio Bandini<sup>19</sup> MD, Chrysoula Liantinioti<sup>20</sup> MD, Lina Palaiodimou<sup>20</sup> MD, Azmil H. Abdul-Rahim<sup>22</sup> MD, Kennedy Lees<sup>22</sup> MD, Michelangelo Mancuso<sup>23</sup> MD, Leonardo Pantoni<sup>24</sup> MD, Silvia Rosa<sup>24</sup> MD, Pierluigi Bertora<sup>24</sup> MD, Silvia Galliazzo<sup>25</sup> MD, Walter Ageno<sup>25</sup> MD, Elisabetta Toso<sup>26</sup> MD, Filippo Angelini<sup>26</sup> MD, Alberto Chiti<sup>27</sup> MD, Giovanni Orlandi<sup>27</sup> MD, Licia Denti<sup>28</sup> MD, Yuriy Flomin<sup>29</sup> MD, Simona Marcheselli<sup>30</sup> MD, Nicola Mumoli<sup>31</sup> MD, Alexandra Rimoldi<sup>31</sup> MD, Elena Verrengia<sup>31</sup> MD, Erika Schirinzi<sup>32</sup> MD, Massimo Del Sette<sup>32</sup> MD, Panagiotis Papamichalis<sup>33</sup> MD, Apostolos Komnos<sup>33</sup> MD, Nemanja Popovic<sup>34</sup> MD, Marija Zarkov<sup>34</sup> MD, Alessandro Rocco<sup>35</sup> MD, Marina Diomedi<sup>35</sup> MD, Elisa Giorli<sup>36</sup> MD, Alfonso Ciccone<sup>2</sup> MD, Brian C Mac Grory<sup>37</sup> MD, Karen L Furie<sup>37</sup> MD, Bruno Bonetti<sup>9</sup> MD, Valentina Saia<sup>10</sup> MD, Francesca Guideri<sup>11</sup> MD, Maurizio Acampa<sup>11</sup>MD, Giuseppe Martini<sup>11</sup> MD, Elisa Grifoni<sup>12</sup> MD, Marina Padroni<sup>14</sup> MD, Efstathia Karagkiozi<sup>15</sup> MD, Kalliopi Perlepe<sup>15</sup> MD, Konstantinos Makaritsis<sup>15</sup> MD, Marina Mannino<sup>17</sup> MD, Miriam Maccarrone<sup>23</sup> MD, Leonardo Ulivi<sup>23</sup> MD, Nicola Giannini<sup>23</sup> MD, Elena Ferrari<sup>23</sup> MD, Alessandro Pezzini<sup>38</sup> MD, Boris Doronin<sup>39</sup> MD, Vera Volodina<sup>39</sup> MD, Antonio Baldi<sup>40</sup> MD, Cataldo D'Amore<sup>40</sup> MD, Dirk Deleu<sup>41</sup> MD, Francesco Corea<sup>42</sup> MD, Jukka Putaala<sup>43</sup> MD, Paola Santalucia<sup>44</sup> MD, Katuscia Nardi<sup>45</sup> MD, Angela Risitano<sup>46</sup> MD, Danilo Toni<sup>46</sup> PhD, Georgios Tsivgoulis<sup>20,21,47</sup> MD.

<sup>1</sup>Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy

<sup>2</sup>S.C. di Neurologia e S.S. di Stroke Unit, ASST di Mantova, Mantova, Italy

<sup>3</sup>University Center for Medicine of Aging & Rehabilitation, University of Basel, Felix-Platter Hospital Basel

<sup>4</sup>Neurology Unit, Stroke Unit, IRCCS, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

<sup>5</sup>New York University Langone Health

<sup>6</sup>Centre Cérébrovasculaire, Service de Neurologie, Département des Neurosciences Cliniques Centre Hospitalier Universitaire Vaudois, Lausanne (Switzerland)

- <sup>7</sup>Department of Neurology, Bogomolets National Medical University, Kyiv, Ukraine  
<sup>8</sup>Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea  
<sup>9</sup>SSO Stroke Unit, UO Neurologia, DAI di Neuroscienze, AOUI Verona, Italy  
<sup>10</sup>Stroke Unit-Department of Neurology, Santa Corona Hospital, Pietra Ligure (Savona), Italy  
<sup>11</sup>Stroke Unit, AOU Senese, Siena, Italy  
<sup>12</sup>Internal Medicine, San Giuseppe Hospital, Empoli, Italy  
<sup>13</sup>Department of Neurology, University Hospital of Ioannina, Greece  
<sup>14</sup>U.O. Neurologia Presidio Ospedaliero di Ravenna Azienda USL della Romagna, Italy  
<sup>15</sup>Department of Medicine, University of Thessaly, Larissa, Greece  
<sup>16</sup>Stroke Unit, Metropolitan Hospital, Piraeus, Greece  
<sup>17</sup>Stroke Unit, Ospedale Civico, Palermo, Italy  
<sup>18</sup>Department of Neurology, Saarland University Medical Center, Homburg, Germany  
<sup>19</sup>Department of Neurology, Ospedale San Paolo, Savona, Italy  
<sup>20</sup>Second Department of Neurology, “Attikon” Hospital, National & Kapodistrian University of Athens, School of Medicine, Athens, Greece  
<sup>21</sup>Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece  
<sup>22</sup>Medical School and Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.  
<sup>23</sup>Clinica Neurologica – Azienda Ospedaliero-Universitaria, Pisa, Italy  
<sup>24</sup>Neurology, 'L. Sacco' Department of Biomedical and Clinical Sciences, University of Milan  
<sup>25</sup>Department of Medicine and Surgery, University of Insubria, Ospedale di Circolo Varese, Italy  
<sup>26</sup>Division of Cardiology, University of Torino, Città della Salute e della Scienza Hospital, Torino, Italy  
<sup>27</sup>Neurologia, Ospedale Apuano, Massa Carrara, Italy  
<sup>28</sup>Stroke Unit - Dipartimento Geriatrico Riabilitativo – University of Parma, Italy  
<sup>29</sup>Stroke and Neurorehabilitation Unit MC ‘Universal Clinic ‘Oberig’ Kyiv, Ukraine  
<sup>30</sup>Neurologia d'urgenza e Stroke Unit, Istituto Clinico Humanitas, Rozzano, Milano, Italy  
<sup>31</sup>Department of Internal Medicine, Magenta Hospital, Magenta, Italy  
<sup>32</sup>Struttura Complessa di Neurologia, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.  
<sup>33</sup>Internist-Intensive Care Specialist, Intensive Care Unit, General Hospital of Larissa, Larissa, Greece  
<sup>34</sup>Clinic of Neurology, Clinical Center Vojvodina, University of Novi Sad, Serbia  
<sup>35</sup>Stroke Unit, Department of Systems Medicine, University of Tor Vergata, Rome, Italy  
<sup>36</sup>Stroke Unit, Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy  
<sup>37</sup>Division of Stroke and Cerebrovascular Diseases, Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, RI, USA  
<sup>38</sup>Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Italy  
<sup>39</sup>Municipal Budgetary Healthcare Institution of Novosibirsk. City Clinical Hospital # 1. Novosibirsk (Russia) at the Novosibirsk State Medical University (Russia)  
<sup>40</sup>Stroke Unit, Ospedale di Portogruaro, Portogruaro (Venice), Italy  
<sup>41</sup>Neurology, Hamad Medical Corporation, Doha, Qatar  
<sup>42</sup>UO Gravi Cerebrolesioni, San Giovanni Battista Hospital, Foligno  
<sup>43</sup>Department of Neurology, Helsinki University Hospital, Helsinki, Finland  
<sup>44</sup>Neurologia, Ospedale Piemonte, IRCCS Bonino Pulejo, Messina, Italy  
<sup>45</sup>Neurologia, Ospedale di Macerata, Italy  
<sup>46</sup>Department of Neurology and Psychiatry, Sapienza University of Rome, Italy  
<sup>47</sup>Department of Neurology, University of Tennessee Health Science Center, Memphis.

Corresponding author:

Maurizio Paciaroni

Stroke Unit and Division of Internal and Cardiovascular Medicine

University of Perugia

Santa Maria della Misericordia Hospital, Perugia – Italy

Email: maurizio.paciaroni@unipg.it

Tel and fax: ++39.075.5782765

Twitter: @m\_paciaroni

Word count: 5307

Tables: 4

Key words: stroke, atrial fibrillation, direct anticoagulants, prevention

Cover title: The ReNo study

## **Abstract**

**Background and Purpose:** Despite treatment with oral anticoagulants patients with non-valvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case–control study in patients with AF were to identify the etiology of and the risk factors for cerebrovascular ischemic events occurring during non-vitamin K antagonists (NOACs) therapy for stroke prevention.

**Methods:** Cases were consecutive patients with AF who had acute cerebrovascular ischemic events during NOACs treatment. Controls were consecutive patients with AF who did not have cerebrovascular events during NOACs treatment.

**Results:** Overall, 713 cases [641 ischemic strokes and 72 TIAs; median age 80.0 years, Interquartile Range (IQR) 12; median NIHSS on admission 6.0 IQR 10] and 700 controls (median age 72.0 years, IQR 8) were included in the study. Recurrent stroke was classified as cardioembolic in 455 cases (63.9%) according to the A-S-C-O-D classification. On multivariable analysis, off-label low dose of NOACs (OR 3.18; 95% CI 1.95-5.85), atrial enlargement (OR 6.64; 95% CI 4.63-9.52), hyperlipidemia (OR 2.40; 1.83-3.16) and CHA<sub>2</sub>DS<sub>2</sub>VASc score (OR 1.72 for each point increase; 95% CI 1.58-1.88) were associated with ischemic events. Among the CHA<sub>2</sub>DS<sub>2</sub>VASc components, age was older and presence of diabetes, congestive heart failure and history of stroke or TIA more common in patients who had acute cerebrovascular ischemic events. Paroxysmal AF was inversely associated with ischemic events (OR 0.45; 0.33-0.61).

**Conclusions:** In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic etiology, off-label low dose, atrial enlargement, hyperlipidemia and high CHA<sub>2</sub>DS<sub>2</sub>VASc score were associated with increased risk of cerebrovascular events.

## **Introduction**

Clinical trials on the prevention of stroke in patients with atrial fibrillation (AF) have consistently shown a benefit associated with oral anticoagulant therapy. Despite an adequate treatment with vitamin K antagonists, some patients with AF still suffer ischemic cerebrovascular events (1). Non-vitamin K antagonist oral anticoagulants (NOACs) are currently recommended as the preferred anticoagulant strategy for patients with non-valvular AF, given their more favorable risk benefit profiles over warfarin (2-4).

The aims of this multicenter case–control study in patients with AF on NOACs for stroke prevention were to identify the etiology of and the risk factors for cerebrovascular ischemic events which occurred during therapy with NOACs.

## **Methods**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Causes and risk factors of cerebral ischemic events in patients with non-valvular atrial fibrillation treated with NOACs for stroke prevention (ReNo) was a multicenter unmatched case-control study performed between January 2016 and June 2018. Consecutive patients with AF who experienced an acute ischemic stroke and had been prescribed NOACs (dabigatran, apixaban, rivaroxaban or edoxaban) for stroke prevention were included in the study. These patients, identified as cases, were enrolled in 37 Stroke Units across Europe, North America and Asia. Controls were patients with AF who had been taking NOACs for stroke prevention for more than 1 month and did not suffer cerebrovascular events after the initiation of anticoagulant therapy. Controls were consecutive outpatients attending four European Anticoagulant Therapy Services [Torino (358 patients), Perugia (190 patients), Varese (94 patients), Kyiv (46 patients)], and three stroke unit follow-up services (12 patients).

Cases who had suspended anticoagulant therapy at least 24 h before the cerebrovascular event for any reasons and patients who did not guarantee compliance were excluded. To verify compliance, the patients and family members were asked how the prescribed anticoagulant was taken.

The study was approved by the pertinent institutional review boards, if required. Informed consent was obtained from all patients.

## **Risk factors**

For cases and controls, data on known stroke risk factors were collected as following: age, gender, history of hypertension (blood pressure higher than 140/90 mmHg at least twice before acute stroke or already under treatment with antihypertensive drugs), history of diabetes mellitus (fasting glucose level higher than 126 mg/dL pre-prandial on two examinations, glucose level higher than 200 mg/dL postprandial, or HbA1c higher than 6.5%, or under antidiabetic treatment), current cigarette smoking, hyperlipidemia (total cholesterol higher than 200 mg/dL or triglyceride higher than 140 mg/dL or already under lipid lowering therapy), history of symptomatic ischemic heart disease (myocardial infarction, history of angina or previous diagnosis of multiple lesions on thallium heart isotope scan or evidence of coronary disease on coronary angiography), history of symptomatic peripheral arterial disease (intermittent claudication of presumed atherosclerotic origin; or ankle/arm systolic blood pressure ratio lower than 0.85 in either leg at rest, or history of intermittent claudication with previous leg amputation, reconstructive surgery, or angioplasty), alcohol abuse (more than 300 g per week), obesity (body mass index higher than 30 kg/m<sup>2</sup>), or previous stroke/TIA. Likewise, baseline variables were obtained for all patients including creatinine clearance (calculated by Cockcroft-Gault equation), type and duration of NOAC treatment. The doses of NOACs were recorded and the reasons for prescribing low doses were also collected. Low doses of NOACs were considered off-label in the absence of the recommended clinical and laboratory criteria for dose reduction (5-8). Low dose of dabigatran was considered as labelled for elderly patients (age  $\geq 80$  years), patients with moderate renal impairment (creatinine clearance 30–49 mL/min) and those with concomitant use of interacting drugs (e.g., verapamil). Low dose of rivaroxaban was considered as labelled for patients with moderate or severe renal impairment (creatinine clearance 15–49 mL/min). Low dose apixaban was considered as labelled for patients with at least two of the following: age  $\geq 80$  years, weight  $\leq 60$  kg, or serum creatinine  $\geq 1.5$  mg/dL. Low dose edoxaban was considered label in patients with moderate or severe renal impairment (creatinine clearance 15–49 mL/min), in those with concomitant use of interacting drugs and in those with a weight  $\leq 60$  kg.

Non-valvular AF was classified as: 1) paroxysmal: associated with episodes terminating spontaneously within seven days; 2) persistent: associated with episodes lasting more than seven days or requiring pharmacological and/or electrical cardioversion; 3) permanent: persisting for more than one year, either

because cardioversion failed or was not pursued (9). For the purpose of the present study, AF was classified into two types: paroxysmal or sustained (persistent or permanent).

For cases, the CHA<sub>2</sub>DS<sub>2</sub>VASc score (2 points for history of stroke or age older than 75 years and 1 point each for congestive heart failure, hypertension, diabetes, vascular disease, age between 65 to 74 years and female sex) was calculated before the cerebrovascular event. For controls, the CHA<sub>2</sub>DS<sub>2</sub>VASc score was calculated at the time of anticoagulant therapy initiation.

A trans-thoracic echocardiogram (TTE) was performed within 7 days from stroke onset in cases and during follow up in controls by a local cardiologist using a standardized protocol. Patients were imaged in the left lateral decubitus. Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal (standard long- and short-axis images) and apical views (standard long-axis, two- and four- chamber images). Standard two-dimensional and color Doppler data, triggered to the QRS complex, were saved in cine loop format. Pulsed and continuous wave Doppler data were also stored digitally. Left atrial enlargement was defined following the American Society of Echocardiography guidelines and the European Association of Echocardiography (10,11).

### **Characteristics of patients with acute stroke or TIA during NOACs treatment**

On admission, in all cases with acute ischemic stroke or TIA, stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS). A non-contrast cerebral computed tomography (CT) or cerebral magnetic resonance imaging (MRI) scan was performed on admission in all patients to exclude intracranial hemorrhage. All patients underwent angio-CT or MRI scan to assess intracranial stenosis and an ultrasonography examination of the carotid and vertebral arteries (12-14). Occlusion of an artery in the territory of the infarct was defined as an absence of flow and the presence of a visible plaque. For the latter, the occlusion was considered to be atherosclerotic.

For the causes of stroke, the A-S-C-O-D classification was used (15,16). A-S-C-O-D phenotyping (A: atherosclerosis; S: small-vessel disease; C: cardiac pathology; O: other causes; D: dissection) assigns a degree of likelihood of causal relationship to every potential disease (1 for potentially causal, 2 for causality is uncertain, 3 for unlikely causal but the disease is present, 0 for absence of disease, and 9 for insufficient

workup to rule out the disease) commonly encountered in ischemic stroke describing all underlying diseases in every patient.

White matter changes [leukoaraiosis defined on the first CT (or MR) examination as ill-defined and moderately hypodense (or hyperintensity on T2-weighted on MR) areas larger than 5 mm according to published criteria] were investigated (17). Leukoaraiosis in the deep white matter was dichotomized into absent versus present.

### **Statistical analysis**

The aims of the unmatched analyses were to identify predictors of ischemic events. Univariate tests ( $\chi^2$  test or Fisher's exact test with Yate's correction when appropriate) were used to compare patients with ischemic events (cases) with controls, regarding risk factors for stroke. Multivariable logistic regression analysis was performed to identify independent predictors for ischemic events. The variables included in this latter analysis were: CHA<sub>2</sub>DS<sub>2</sub>VASc score (separately as a continuous variable or including the risk factors within the score excluding the CHA<sub>2</sub>DS<sub>2</sub>VASc score), hyperlipidemia, alcohol abuse, paroxysmal AF, atrial enlargement and dose of NOACs. The variables low dose and off-label low dose were inserted into the multivariable model separately. Moreover, a sensitivity analysis after matching for age was performed. Data were analyzed with the SPSS/PC Win package 25.0.

#### *Sample size calculation.*

For this unmatched case-control study, it was assumed that at least 15% of controls would have had the risk factor with the lower incidence. In order to detect a minimum odds ratio of 1.5 with a power of 80% and an alpha risk of 5%, it was calculated that a total of 1,308 patients would have been needed (ratio controls/cases 1:1) (18).

## **Results**

### **Characteristics and causes of cerebrovascular events occurring during anticoagulant therapy**

During the study period, 713 consecutive patients on NOACs were admitted for an acute cerebrovascular event (641 ischemic strokes and 72 TIAs). The median age of these patients was 80.0 years, Interquartile Range (IQR) 12 and median NIHSS on admission was 6.0, IQR 10. Atherosclerotic lesions were detected in



420 patients (58.9%): extracranial ICA stenosis 30-49% in 190 (26.6%), extracranial ICA stenosis  $\geq$ 50% in 95 (13.3%), vertebral/basilar artery stenosis  $\geq$ 50% in 33 (4.6%), intracranial stenosis in the anterior circulation 30-49% in 26 (3.6%), intracranial stenosis in the anterior circulation  $\geq$ 50% in 41 (5.7%) and stenosis in more than one location in 38 patients (5.3%). Leukoaraiosis was found in 404 patients (56.7%). The index event occurred after an average of 14.4 months from initiation NOACs. Concerning the causes of the index events, 455 (63.9%) were considered cardioembolic strokes, according to A-S-C-O-D classification (Table 1).

### **Predictors of cerebrovascular ischemic events during anticoagulant therapy**

The 713 cases were compared to a control group of 700 controls (median age 72.0 years, IQR 8). The characteristics of cases and controls are summarized in Table 2.

On univariable analysis, cases with ischemic events were older, had a higher prevalence of vascular risk factors and atrial enlargement on TTE. Among the cases, 317 (44.5%) were treated with low doses of NOACs compared to 207 (29.6%) of controls. Of the 317 cases treated with low doses, 111 (35.0%) were treated with off-label low doses compared to 53 of the 207 controls (27.5%) treated with off-label low dose. Of the 111 cases treated with off-label low dose, 38 were treated with low dose because of “fear” of bleeding, 10 had history of bleeding, 7 were prescribed concomitant antiplatelet therapy and 46 for other causes (cost of the drug, recurrent falls, amyloid angiopathy, anemia, history of cancer, age, misinterpretation of the patient, preference of the patient, gastro-intestinal discomfort and hypertension); in 10 patients, the cause remains unknown. Of the 53 controls treated with off-label low dose, 6 were treated with off-label low dose because of “fear” of bleeding, 10 had history of bleeding, 6 were prescribed concomitant antiplatelet therapy and 31 for other causes (recurrent falls, amyloid angiopathy, anemia, history of tumor, age, misinterpretation of the patient, preference of the patient, gastro-intestinal discomfort and hypertension).

The results of multivariable and the sensitivity analyses are reported in Table 3. Patients treated with off-label low doses and the presence of atrial enlargement, especially when severe, had a higher risk of ischemic events (OR 3.18; 95% CI 1.95-5.85,  $p=0.0001$  and OR 6.64; 95% CI 4.63-9.52,  $p=0.0001$ , respectively).

Additionally, CHA<sub>2</sub>DS<sub>2</sub>VASc score was associated with the occurrence of ischemic events (OR 1.72 for each point increase; 95% CI 1.58-1.88, p=0.0001).

The characteristics of the patients with cerebrovascular events treated with low doses are summarized in Table 4. On multivariable analysis, CHA<sub>2</sub>DS<sub>2</sub>VASc score was associated with prescription of low dose NOACs (OR 1.35 for each point increase; 95% CI 1.20-1.52, p=0.0001). Low clearance of creatinine was associated with prescription of low dose NOACs (OR 0.98 for 1 ml/min increase; 95% CI 0.97-0.99, p=0.001).

## **Discussion**

This unmatched case-control study showed that the main risk factor associated with an increased risk of ischemic cerebrovascular events was the administration of a low dose of NOACs. Specifically, 40-45% of the patients with ischemic events had been prescribed reduced doses of NOACs, and about 35% of these had been prescribed reduced off-label doses. The prescription of low dose was associated with higher CHA<sub>2</sub>DS<sub>2</sub>VASc score. The ORBIT II AF study reported that 1 in 7 patients treated with a NOAC were prescribed with a reduced dose of NOACs. Notably, more than half of the NOAC reductions were inconsistent with Food and Drug Administration (FDA) or European Medicines Agency (EMA) labeling and appeared to be unexplainably in patients with lower bleeding risk. In unadjusted analyses, patients receiving reduced NOAC doses had high crude adverse event rates, particularly those who should have received standard NOAC dosing. Although these results were consistent in adjusted analyses, the differences were not statistically significant (19).

In the ReNo study, about 30% of the patients with cerebrovascular events had stroke due to causes other than cardio-embolism. Indeed, ischemic stroke in patients with AF is not thought to be exclusively cardiogenic. For this reason, in patients with stroke during anticoagulation therapy, the first step should be to confirm the etiology of the new event that more than often requires adjustments of the original treatment strategy.

The presence of hyperlipidemia and the type of AF were independently associated with risks of cerebrovascular events in this study. Currently, these two variables are not represented in any international guideline risk scores for stroke in patients with AF. Therefore, it is plausible that by adding these two variables to currently used scores better predictions of risk could be obtained.

The ReNo study has the following limitations: 1) it was observational, and neither individual NOAC or their doses were randomized; 2) other pharmacological treatments besides NOACs were not investigated.

Interactions between NOACs and other drugs are reported to be much lower than that of warfarin.

Specifically, all currently available NOACs are substrates of the P-glycoprotein transporter, one-third of rivaroxaban is metabolized by the liver via CYP3A4/CYP3A5 and CYP2J2-dependent pathways and

apixaban which has predominant non-renal clearance is eliminated via the CYP3A4, CYP1A2 and CYP2J2-dependent pathways. Therefore, it is plausible that drug interactions may have interfered with the

anticoagulant effect; 3) we excluded patients who could not guarantee adherence to the prescribed treatment regimen. As this information was provided by the patients themselves or the care-giver, a laboratory

assessment of the anticoagulant status during the event might have been informative (20,21); 4) we did not

collect data regarding any possible off-label overdose of NOACs; which has been reported in literature to be about 3% (22); 5) the bleeding risk of the patients included in the ReNo study remained unknown;

6) Cases were collected from a number of Stroke Units in Europe, United States and Asia. Unfortunately, not all participating Stroke Units have an associated anticoagulant unit where the cases could have been collected. For this reason, we collected control data in 7 centers, all except one, associated to a Stroke Unit.

The strengths of our study include its adequate sample size and its prospective design. Additionally, our analyses reflect real-life experiences and thus, may provide valuable information that could significantly reduce the incidence of ischemic events in patients with AF and stroke during NOAC therapy.

Conclusion: In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic etiology, off-label low dose, atrial enlargement, hyperlipidemia and high CHA<sub>2</sub>DS<sub>2</sub>VASc score were associated with increased risk of cerebrovascular events.

## **Disclosures**

Maurizio Paciaroni received honoraria as a member of the speaker bureau of Aspen, Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol Meyer Squibb, Daiichi Sankyo and Pfizer.

Giancarlo Agnelli received honoraria as a member of the speaker bureau of Boehringer Ingelheim and Bayer.

Valeria Caso received honoraria as a member of the speaker bureau of Boehringer Ingelheim, Bayer, Daiichi Sankyo (all fees were paid to A.R.S. – Associazione Ricerca Stroke - Umbria). She received honoraria as consultant or advisory board of Boehringer Ingelheim, Bayer, Daiichi Sankyo and Pfizer.

Stefan T. Engelter has received funding for travel or speaker honoraria from Bayer, Boehringer Ingelheim and Daiichi-Sankyo. He has served on scientific advisory boards for Bayer, Boehringer Ingelheim, BMS/Pfizer, and MindMaze and on the editorial board of Stroke. He has received an educational grant from Pfizer, and research support from Daiichi-Sankyo, compensation from Stago for educational efforts and research support from the Science Funds [Wissenschaftsfonds] of the University Hospital Basel, the University Basel, the “Freiwillige Akademische Gesellschaft Basel”, the Swiss Heart Foundation, and the Swiss National Science Foundation.

Patrik Michel received research funding from the Swiss Heart Foundation. He received consultant honoraria by Medtronic.

George Ntaios received research funding from Pfizer. He received honoraria from Pfizer, Boehringer Ingelheim and Bayer. He received consultant honoraria from Pfizer, Boehringer Ingelheim and Bayer.

David Julian Seiffge received research funding from the Swiss National Science Foundation, the Bangerter-Rhyner Foundation, the Swiss Society of Neurology and the Bayer Foundation (Thrombosis Award 2017). He received speaker honoraria/advisory board fees from Bayer AG and Pfizer and compensation for educational efforts from STAGO.

Gian Marco De Marchis has received consultant and travel honoraria by Bayer; speaker honoraria by Medtronic and BMS/Pfizer. He was supported from the Swiss National Science Foundation; Spezialprogramm Nachwuchsförderung Klinische Forschung, University of Basel; Swiss Heart Foundation; Bangerter-Rhyner-Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli; De Quervain research grant; Thermo Fisher GmbH.

Georgios Tsivgoulis has received funding for travel or speaker honoraria from Bayer and Boehringer Ingelheim. He has served on scientific advisory boards for Bayer, Boehringer Ingelheim and Daiichi-Sankyo.

Jukka Putaala received research funding from Pfizer. He received honoraria for lectures related to atrial fibrillation and anticoagulants for Pfizer, Bayer and Boehringer Ingelheim. He received consultant honoraria from Bayer, Boehringer Ingelheim, Pfizer and MSD.

Kennedy Lees reports fees and expenses from Boehringer Ingelheim for serving on independent data monitoring committees.

Massimo Del Sette has received honoraria for speaking from Bayer and Boehringer Ingelheim.

Walter Ageno has received speaker's honoraria from, and participated in scientific advisory boards for, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Portola, Aspen, Sanofi and Daiichi Sankyo.

Francesco Corea reports expenses for meeting from Novartis.

Danilo Toni received honoraria as a member of speaker bureau from Boehringer Ingelheim, Bayer, Pfizer and Daiichi Sankyo. He received consultant honoraria as advisory board of Boehringer Ingelheim, Pfizer, Bristol Meyer Squibb, Daiichi Sankyo and Bayer.

The other authors have nothing to disclose.

## **Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## References

1. Paciaroni M, Agnelli G, Ageno W, Caso V, Corea F, Lanari A, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. *Atherosclerosis* 2010; 212:564–566.
2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;383:955–62.
3. Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR et al. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. *Ther Adv Neurol Disord*. 2016;9:359-68.
4. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. *Int J Stroke*. 2017;12:589-596.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–1151.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;365:883–891.
7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;365:981–992.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;369:2093-104.
9. Lévy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns HJ et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *J Cardiovasc Electrophysiol* 2003; 14: 443–445.

10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standard Committee and the Chamber Quantification Writing Group, Developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005; 18:1440–1463.
11. Pepi M, Evangelista A, Nihoyannopoulos P, Flachskampf FA, Athanassopoulos G, Colonna P et al. European Association of Echocardiography. Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism. *Eur J Echocardiogr* 2010; 11: 461-476.
12. Alexandrov AV, Brodie DS, McLean A, Hamilton P, Murphy J, Burns PN. Correlation of peak systolic velocity and angiographic measurement of carotid stenosis revisited. *Stroke* 1997;28:339–42.
13. Eliasziw M, Rankin RN, Fox AJ, Haynes RB, Barnett HJM. Accuracy and prognostic consequences of ultrasonography in identifying severe carotid artery stenosis. *Stroke* 1995;26:1747–5.
14. Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MI: A standardized method for measuring intracranial arterial stenosis. *Am J Neuroradiol* 2000; 21:643–646.
15. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New Approach to Stroke Subtyping: The A-S-C-O (Phenotypic) Classification of Stroke. *Cerebrovasc Dis* 2009; 27: 502-508.
16. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO phenotyping). *Cerebrovasc Dis* 2013; 36: 1-5.
17. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin A, Sjogren M et al. A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke*. 2001;32:1318 –1322.
18. Lemeshow, Stanley, Hosmer, David W, Klar, Janelle, Lwanga, Stephen Kagawa & World Health Organization, 1990. Chichester : Wiley. <http://www.who.int/iris/handle/10665/41607>
19. Steinberg BA, Shrader P, Thomas ML, Ansell J, Fonarow GC, Gersh BJ, et al. for the ORBIT-AF Investigators and Patients. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. *J Am College Cardiol* 2016; 68: 2597-2604.

20. Tripodi A, Chantarangkul V, Legnani C, Testa S, Tosetto A. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme. *J Thromb Haemost.* 2018;16:565-570.
21. Ebner M, Birschmann I, Peter A, Härtig F, Spencer C, Kuhn J et al. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions. *Stroke.* 2017;48:2457-2463.
22. Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) II Investigators. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). *J Am Heart Assoc.* 2018: e007633. doi: 10.1161/JAHA



**Table 1:** The etiology of cerebrovascular events in patients on NOACs for stroke prevention

Etiology of stroke	ASCOD classification		
Cardioembolic (CE)	[A(0,2,3)-S(0,2,3)-C1-O(0,2,3)]	455	63.9%
Other possible causes		233	32.7%
Large Artery Disease (LAD)	[A1,S(0,2,3)-C(2,3)-O(0,2,3)]	24	3.3%
Small Vessel Disease (SVD)	[A(0,2,3)-S1-C(2,3)-O(0,2,3)]	74	10.4%
Other Causes (Other)	[A(0,2,3)-S(0,2,3)-C(2,3)-O1]	29	4.1%
CE and LAD	[A1-S(0,2,3)-C1-O(0,2,3)]	65	9.1%
CE and SVD	[A(0,2,3)-S1-C1-O(0,2,3)]	29	4.1%
CE and Other	[A(0,2,3)-S(0,2,3)-C1-O1]	5	0.7%
CE and LAD and SVD	[A1-S1-C1-O(0,2,3)]	3	0.4%
LAD and SVD	[A1-S1-C(2,3)-O(0,2,3)]	4	0.6%
ASCOD not collected		24	3.4%
Total		713	100%

**Table 2.** Characteristics of the cases and controls

	Cases (n=713)	Controls (n=700)	P
Age (years), mean (median)	78.1±9.1 (80.0)	71.3±11.3 (72.0)	0.0001
Females	375 (52.6%)	256 (36.6%)	0.0001
Duration of therapy (mean, months)	14.4±12.0	29.1±21.0	0.0001
Apixaban	221 (31.0%)	223 (31.8%)	0.7
Dabigatran	199 (27.9%)	160 (22.8%)	0.03
Edoxaban	43 (6.0%)	26 (3.8%)	0.04
Rivaroxaban	250 (35.1%)	291 (41.6%)	0.01
Low dose NOACs	317 (44.5%)	207 (29.6%)	0.0001
Non-label low dose	111/317 (35.0%)	53/207 (25.6%)	0.03
Creatinine clearance, mean (median)	66.5±25.1 (63.0)	76.3±25.9 (76.0)	0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc score≥4	607 (85.1%)	318 (45.4%)	0.0001
Hypertension	608 (85.3%)	562 (80.3%)	0.01
Diabetes Mellitus	203 (28.5%)	120 (17.1%)	0.0001
Hyperlipidemia	387 (54.3%)	192 (27.4%)	0.0001
Alcohol abuse	101 (14.2%)	118 (16.8%)	0.01
Current smoker	132 (18.5%)	116 (16.6%)	0.2
Congestive heart failure	223 (31.3%)	148 (21.1%)	0.0001
History stroke/TIA	339 (47.5%)	173 (24.7%)	0.0001
Myocardial infarction	174 (24.4%)	148 (21.1%)	0.1
Peripheral artery disease	123 (17.2%)	41 (5.9%)	0.0001
Paroxysmal AF	177 (24.8%)	289 (41.3%)	0.0001
Atrial enlargement on TTE	509/607 (83.9%)	154/431 (35.7%)	0.0001
Moderate	125/607 (20.6%)	44/431 (10.2%)	
Severe	168/607 (27.7%)	18/431 (4.2%)	

**Table 3:** Multivariable and sensitivity analyses: predictive factors for ischemic stroke or TIA

	OR (95% CI)	p	Sensitivity analysis OR (95% CI)	p
Low dose NOACs	1.23 (0.93-1.65)	0.1	1.09 (0.72-1.63)	0.6
Non-label low dose	3.18 (1.95-5.85)	0.0001	3.56 (1.72-7.37)	0.001
Hyperlipidemia	2.40 (1.83-3.16)	0.0001	2.82 (1.93-4.11)	0.0001
Alcohol abuse	0.90 (0.62-1.30)	0.5	0.92 (0.57-1.48)	0.7
Current smoker	1.19 (0.84-1.69)	0.3	1.25 (0.77-2.02)	0.4
Paroxysmal AF	0.45 (0.33-0.61)	0.0001	0.37 (0.25-0.54)	0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc score	1.72 (1.58-1.88)	0.0001	1.31 (1.16-1.48)	0.0001
Age	1.09 (1.07-1.10)	0.0001		
Females	1.31 (0.99-1.73)	0.054		
Hypertension	0.83 (0.57-1.20)	0.3		
Diabetes Mellitus	1.80 (1.30-2.40)	0.0001		
Congestive heart failure	1.45 (1.06-1.93)	0.02		
History stroke/TIA	1.48 (1.12-1.96)	0.006		
Vascular disease (myocardial infarction and/or peripheral arterial disease)	0.88 (0.65-1.19)	0.4		
In patients with TTE (n=1034):				
Atrial enlargement (yes/no)	6.64 (4.63-9.52)	0.0001	4.05 (2.75-5.95)	0.0001
No atrial enlargement	1 (Ref.)	0.0001		
Mild atrial enlargement	4.29 (2.71-6.77)			
Moderate atrial enlargement	8.06 (4.80-13.53)			
Severe atrial enlargement	23.28 (12.58-43.07)			

**Table 4.** Characteristics of the patients with cerebrovascular events treated with low dose of NOACs

	Low dose (n=317)	Standard dose (n=396)	p
Age (years), mean (median)	81.9±8.6 (82.0)	75.3±8.8 (76.0)	0.0001
Females	200 (63.1%)	171 (43.2%)	0.001
Creatinine clearance, mean (median)	57.3±23.7 (55.0)	70.7±23.5 (67.0)	0.0001
CHA <sub>2</sub> DS <sub>2</sub> VASc score≥4	293 (92.4%)	314 (79.3%)	0.0001
Hypertension	279 (88.0%)	329 (83.1%)	0.1
Diabetes Mellitus	94 (29.6%)	109 (27.5%)	0.5
Hyperlipidemia	161 (50.8%)	226 (57.1%)	0.08
Alcoholism	34 (10.7%)	67 (16.9%)	0.01
Current smoker	39 (12.3%)	93 (23.5%)	0.0001
Congestive heart failure	105 (33.1%)	120 (31.5%)	0.5
History of stroke/TIA	155 (48.9%)	183 (46.2%)	0.6
Myocardial infarction	112 (35.3%)	138 (43.8%)	1.0
Peripheral artery disease	43 (13.6%)	81 (20.4%)	0.02
Paroxysmal AF	141 (44.5%)	148 (37.4%)	0.1
Leukoaraiosis	200 (63.1%)	205 (51.8%)	0.001